Eric Topol· @EricTopol · X·· 1 天前AI 评分42
AI 导读
个性化新抗原疫苗已被证明可改善难治性恶性黑色素瘤的预后，在胰腺癌、胶质母细胞瘤、肾细胞癌和三阴性乳腺癌的初步研究中也有类似表现。但这些疫苗需要肿瘤活检来识别抗原。一项新研究表明，可以从血液样本中获取这些信息。 https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-1779/788486/Peripheral-Blood-as-the-Sole-Source-for-Cancer
正文
Personalized neoantigen vaccines have already been shown to improve outcomes for refractory malignant melanoma and in pilot studies of pancreatic cancer, glioblastoma, renal cell carcinoma and triple negative breast cancer. But they require a tumor biopsy to identify the antigens. A new study shows it's possible to get this from a blood sample.
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-1779/788486/Peripheral-Blood-as-the-Sole-Source-for-Cancer
来源：Eric Topol · x.com